Impact of neoadjuvant chemotherapy on perioperative morbidity after major surgery for head and neck cancer.

Patients undergoing NAC appear to have a higher disease burden but tend to be younger and healthier. Within the context of this inherent selection bias, NAC does not appear to increase perioperative morbidity among patients undergoing surgery for HNC.